<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-148244" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Nirmatrelvir-Ritonavir</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lam</surname>
            <given-names>Clinton</given-names>
          </name>
          <aff>Touro University Nevada College of Osteopathic Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Clinton Lam declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-148244.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Nirmatrelvir/ritonavir also referred to as ritonavir-boosted nirmatrelvir, is an oral combination medication used to treat coronavirus disease 2019 (COVID-19). It consists of nirmatrelvir, a protease inhibitor targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease, and ritonavir, a cytochrome P450 (CYP) 3A inhibitor. Nirmatrelvir/ritonavir was authorized for emergency use on December 22, 2021. It is currently one of the highly-effective oral antiviral medications available to treat COVID-19. This activity reviews the medication&#x02019;s indications and contraindications. It also reviews the mechanism of action, administration, monitoring, adverse effects, toxicity, and other elements related to treating patients with COVID-19. Information in this activity is pertinent to all members of the interprofessional healthcare team, including physicians, pharmacists, nurses, and other health professionals, who manage the care of patients with COVID-19.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Outline the indications for using nirmatrelvir/ritonavir.</p></list-item><list-item><p>Explain the potential adverse effects of nirmatrelvir/ritonavir.</p></list-item><list-item><p>Describe the mechanism of action of nirmatrelvir/ritonavir.</p></list-item><list-item><p>Summarize the contraindications of using nirmatrelvir/ritonavir to treat patients with COVID-19.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=148244&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=148244">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-148244.s2" sec-type="Indications">
        <title>Indications</title>
        <p>On December 22nd, 2021, the United States (US) Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for nirmatrelvir/ritonavir, allowing its use in the treatment of COVID-19.<xref ref-type="bibr" rid="article-148244.r1">[1]</xref><xref ref-type="bibr" rid="article-148244.r2">[2]</xref> Specifically, it is used to treat mild-to-moderate COVID-19 in patients who have a SARS-CoV-2-positive test, are at least 12 years of age, weigh at least 40 kilograms (88 pounds), are not hospitalized due to COVID-19, and have a high risk of clinical progression to severe disease which includes hospitalization and death.<xref ref-type="bibr" rid="article-148244.r3">[3]</xref>&#x000a0;</p>
        <p>According to Charlson's comorbidity index, underlying comorbidities associated with severe disease outcomes are chronic pulmonary disease(including asthma), diabetes mellitus, older age, male sex, obesity, coronary artery disease, congestive heart failure, dementia, liver disease,&#x000a0;chronic kidney&#x000a0;disease, solid tumor with metastasis, and immunosuppression.<xref ref-type="bibr" rid="article-148244.r4">[4]</xref><xref ref-type="bibr" rid="article-148244.r5">[5]</xref><xref ref-type="bibr" rid="article-148244.r6">[6]</xref>&#x000a0;</p>
        <p>As demonstrated by the EPIC-HR (Evaluation of Protease Inhibition for Covid-19 in High-Risk Patients) trial, nirmatrelvir/ritonavir in these patients within five days of the onset of symptoms reduced the risk of COVID-19-related hospital admission or death by 89%.<xref ref-type="bibr" rid="article-148244.r7">[7]</xref><xref ref-type="bibr" rid="article-148244.r8">[8]</xref> Studies demonstrate that its&#x000a0;efficacy is comparable to that of remdesivir and greater than that of molnupiravir.<xref ref-type="bibr" rid="article-148244.r9">[9]</xref><xref ref-type="bibr" rid="article-148244.r10">[10]</xref>&#x000a0;Nirmatrelvir/ritonavir is also efficacious against the Omicron variant and its subvariants.<xref ref-type="bibr" rid="article-148244.r11">[11]</xref><xref ref-type="bibr" rid="article-148244.r12">[12]</xref>&#x000a0;</p>
        <p>According to the Centers for Disease Control and Prevention (CDC) report, less&#x000a0;than 1% of patients treated with nirmatrelvir-ritonavir required hospitalization or emergency department care.&#x000a0;&#x000a0;The patients who required hospitalization had advanced age(&#x0003e;60 years).<xref ref-type="bibr" rid="article-148244.r13">[13]</xref><xref ref-type="bibr" rid="article-148244.r14">[14]</xref></p>
      </sec>
      <sec id="article-148244.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Nirmatrelvir/ritonavir is a combination of two medications with distinct mechanisms of action. Nirmatrelvir, the first component, is a peptidomimetic inhibitor of Mpro, the SARS-CoV-2 main protease. Inhibiting Mpro prevents the virus from processing the polyprotein precursors it requires for viral replication.</p>
        <p>Ritonavir, the second component, is a human immunodeficiency virus-1 (HIV-1) protease inhibitor with CYP3A-inhibiting effects. The latter effect allows it to be&#x000a0;used as a pharmacokinetic boosting agent to decrease the CYP3A-mediated metabolism of nirmatrelvir. Coadministration of nirmatrelvir with ritonavir is needed to increase the plasma concentration of nirmatrelvir enough to achieve the targeted therapeutic range.<xref ref-type="bibr" rid="article-148244.r15">[15]</xref>&#x000a0;</p>
        <p>Nirmatrelvir/ritonavir is effective against major variants of&#x000a0;SARS-CoV-2,&#x000a0;including omicron&#x000a0;variants.<xref ref-type="bibr" rid="article-148244.r16">[16]</xref>&#x000a0;The proposed&#x000a0;mechanism of resistance&#x000a0;is&#x000a0;the possibility of potential escape mutations.<xref ref-type="bibr" rid="article-148244.r17">[17]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> The time to maximum plasma concentration (Tmax) for nirmatrelvir(coadministered with&#x000a0;ritonavir) is approximately 3 hours. Administering&#x000a0;high-fat meals with nirmatrelvir/ritonavir increases the rate and extent of absorption.</p>
        <p><bold>Distribution:</bold> Plasma protein binding (PPB) for nirmatrelvir is 69% (coadministered with&#x000a0;ritonavir), PPB of ritonavir 98-99%. The mean volume of Distribution for nirmatrelvir is 104.7 L (coadministered with&#x000a0;ritonavir).</p>
        <p><bold>Metabolism:</bold>&#x000a0;Nirmatrelvir is a human cytochrome CYP3A4 substrate, but when&#x000a0;administered with ritonavir, the metabolic clearance is minimal.&#x000a0;Ritonavir inhibits the metabolism of nirmatrelvir,&#x000a0;leading to&#x000a0;increased plasma concentrations of nirmatrelvir. Ritonavir is also metabolized by CYP2D6(minor).</p>
        <p><bold>Excretion:</bold> The primary route of elimination for nirmatrelvir is renal, whereas ritonavir is eliminated primarily by hepatic metabolism in feces.<xref ref-type="bibr" rid="article-148244.r18">[18]</xref></p>
      </sec>
      <sec id="article-148244.s4" sec-type="Administration">
        <title>Administration</title>
        <p>The standard regimen is nirmatrelvir 300 mg (two 150 mg tablets) and ritonavir 100 mg (one 100 mg tablet), which are orally co-administered twice daily for five days and started within five days of symptom onset. Nirmatrelvir and ritonavir are co-packaged in convenience packs of 300 mg/100 mg or 150 mg/100 mg (for patients with moderate renal impairment).<xref ref-type="bibr" rid="article-148244.r3">[3]</xref></p>
        <p>The medication should be taken at the same time each day. If a dose is missed within eight hours of the time it is typically assumed, it should be taken as soon as possible. However, the missed dose should be skipped if more than eight hours have elapsed. The FDA does not authorize nirmatrelvir/ritonavir&#x000a0;for&#x000a0;treatment&#x000a0;for longer than five days. Additionally, use is not approved for pre-exposure or post-exposure prophylaxis to prevent COVID-19.</p>
        <p>
<bold>Use in Specific Patient Population</bold>
</p>
        <p>
<bold>Renal Impairment</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Dose adjustment is not needed for mild renal impairment (eGFR &#x0003e;60 mL/min to &#x0003c;90 mL/min).</p>
          </list-item>
          <list-item>
            <p>Dose adjustment is needed for moderate renal impairment (eGFR &#x0003e;30 to &#x0003c;60 mL/min).&#x000a0;</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Nirmatrelvir 150 mg (one 150 mg tablet) and ritonavir 100 mg (one 100 mg tablet) are orally co-administered twice daily for five days within five days of symptom onset.</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>Nirmatrelvir/ritonavir is not recommended in those with severe renal impairment (eGFR &#x0003c;30 mL/min).<xref ref-type="bibr" rid="article-148244.r19">[19]</xref>&#x000a0;Use the CKD-EPI formula to calculate eGFR.<xref ref-type="bibr" rid="article-148244.r20">[20]</xref><xref ref-type="bibr" rid="article-148244.r21">[21]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Hepatic Impairment</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Dose adjustment is not needed for mild hepatic impairment (Child-Pugh Class A).</p>
          </list-item>
          <list-item>
            <p>Dose adjustment is not needed for moderate hepatic impairment (Child-Pugh Class B).</p>
          </list-item>
          <list-item>
            <p>Nirmatrelvir/ritonavir is not recommended for those with severe hepatic impairment (Child-Pugh Class C).<xref ref-type="bibr" rid="article-148244.r3">[3]</xref></p>
          </list-item>
        </list>
        <p><bold>Pregnancy Considerations:&#x000a0;</bold>Limited human data is available regarding drug-related risks of congenital disabilities, miscarriage, or other adverse maternal or fetal outcomes using nirmatrelvir in pregnant women. Human data on the use of ritonavir in pregnant women have not shown an increase in the risk of congenital disabilities.</p>
        <p>Animal studies of nirmatrelvir/ritonavir suggest that it can be safely used in pregnant women. Because pregnancy is a risk factor for developing severe COVID-19, nirmatrelvir/ritonavir should be offered to eligible pregnant women based on risk-benefit assessments.<xref ref-type="bibr" rid="article-148244.r22">[22]</xref></p>
        <p><bold>Breastfeeding Considerations:&#x000a0;</bold>Limited human data is available regarding the presence of nirmatrelvir in breast milk or its effects on breastfeeding infants. Human data demonstrate&#x000a0;that ritonavir is present at&#x000a0;low levels in breast milk and breastfed infants' blood.</p>
        <p>Though ritonavir use during pregnancy is unlikely to have significant clinical implications, breastfeeding infants should still be monitored for the development of adverse effects.<bold>&#x000a0;</bold>Additionally, nirmatrelvir has&#x000a0;poor&#x000a0;oral bioavailability, and the&#x000a0;concentration&#x000a0;of ritonavir in milk is small; consequently, the combination of nirmatrelvir/ritonavir is unlikely to cause adverse drug reactions&#x000a0;in nursing&#x000a0;infants.<xref ref-type="bibr" rid="article-148244.r23">[23]</xref></p>
      </sec>
      <sec id="article-148244.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>As nirmatrelvir/ritonavir is an investigational drug, there is limited clinical data about its potential adverse effects. However, data from the EPIC-HR trial suggests that it is generally well-tolerated by patients with COVID-19. The most common adverse effects include dysgeusia, diarrhea, hypertension, and myalgia.<xref ref-type="bibr" rid="article-148244.r3">[3]</xref></p>
        <p>In addition, hypersensitivity reactions, which may manifest&#x000a0;as&#x000a0;urticaria, angioedema, pruritus, and dyspnea, have been reported. Cases of anaphylaxis, Stevens-Johnson syndrome, and toxic epidermal necrolysis have also been reported with ritonavir use. Hyperlipidemia, hypertriglyceridemia,&#x000a0; and other metabolic adverse effects have also been noted with ritonavir.<xref ref-type="bibr" rid="article-148244.r24">[24]</xref>&#x000a0;</p>
        <p>Hepatic transaminase elevations have been reported, but transaminase elevations have also been attributed to COVID-19(A confounding factor). The risk of hepatotoxicity is low, and the Likelihood score is E:(unlikely cause of clinically apparent liver injury).<xref ref-type="bibr" rid="article-148244.r25">[25]</xref></p>
        <p>Nirmatrelvir/ritonavir has significant drug-drug interactions due to the ritonavir component. As a potent CYP3A inhibitor, ritonavir can increase plasma concentrations of concomitant medications, increasing the risks of developing severe and life-threatening drug-related adverse effects. Due to these drug-drug interactions, many CYP3A-metabolized drugs are contraindicated in patients taking nirmatrelvir/ritonavir.<xref ref-type="bibr" rid="article-148244.r24">[24]</xref></p>
        <p>In patients with undiagnosed or uncontrolled HIV-1 infection, there is a theoretical risk that the use of nirmatrelvir/ritonavir will facilitate the development of antiviral cross-resistance against HIV-1 protease inhibitors due to the ritonavir component, which is an HIV-1 protease inhibitor; hence nirmatrelvir/ritonavir use is cautioned in patients with undiagnosed or uncontrolled HIV-1 infection.<xref ref-type="bibr" rid="article-148244.r24">[24]</xref></p>
      </sec>
      <sec id="article-148244.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Nirmatrelvir/ritonavir is contraindicated if the patient has a history of clinically significant hypersensitivity reactions (e.g., anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis) to nirmatrelvir or ritonavir, other drugs in the same class, or drug components.<xref ref-type="bibr" rid="article-148244.r3">[3]</xref></p>
        <p>Moreover, nirmatrelvir/ritonavir is contraindicated with the concomitant use of medications that depend on CYP3A for clearance and whose elevated plasma concentrations are associated with serious and life-threatening adverse reactions which are due to the CYP3A-inhibiting effects of ritonavir, which can increase plasma concentrations of those medications to dangerous levels.<xref ref-type="bibr" rid="article-148244.r26">[26]</xref><xref ref-type="bibr" rid="article-148244.r27">[27]</xref>&#x000a0;</p>
        <p>Below is a partial list of those contraindicated medications and their potential adverse effects according to the FDA&#x000a0;prescriber fact sheet.</p>
        <list list-type="bullet">
          <list-item>
            <p>Alpha-1-adrenoreceptor antagonists (alfuzosin): hypotension</p>
          </list-item>
          <list-item>
            <p>Analgesics (pethidine): respiratory depression, hematologic abnormalities</p>
          </list-item>
          <list-item>
            <p>Antianginals (ranolazine): serious and life-threatening reactions</p>
          </list-item>
          <list-item>
            <p>Antiarrhythmics (amiodarone, dronedarone, flecainide, propafenone, quinidine): cardiac arrhythmias</p>
          </list-item>
          <list-item>
            <p>Anticancer drugs (encorafenib, ivosidenib): QT interval prolongation</p>
          </list-item>
          <list-item>
            <p>Anti-gout drugs (colchicine): severe and life-threatening reactions in renal or hepatic impairment</p>
          </list-item>
          <list-item>
            <p>Antipsychotics (lurasidone, pimozide, clozapine): cardiac arrhythmias</p>
          </list-item>
          <list-item>
            <p>Benign prostatic hyperplasia agents (silodosin): postural hypotension</p>
          </list-item>
          <list-item>
            <p>Cardiovascular agents (eplerenone): hyperkalemia</p>
          </list-item>
          <list-item>
            <p>Cardiovascular agents (ivabradine): bradycardia, conduction disturbances</p>
          </list-item>
          <list-item>
            <p>Ergot derivatives (dihydroergotamine, ergotamine, methylergonovine): acute ergot toxicity</p>
          </list-item>
          <list-item>
            <p>HMG-CoA reductase inhibitors (lovastatin, simvastatin): myopathy (including rhabdomyolysis)</p>
          </list-item>
          <list-item>
            <p>Immunosuppressants (voclosporin): acute and chronic nephrotoxicity</p>
          </list-item>
          <list-item>
            <p>Microsomal triglyceride transfer protein inhibitors (lomitapide): hepatotoxicity, gastrointestinal adverse effects(Possible increase&#x000a0;of AUC 27 fold)</p>
          </list-item>
          <list-item>
            <p>Migraine medications (eletriptan, ubrogepant): cardiovascular and cerebrovascular adverse events</p>
          </list-item>
          <list-item>
            <p>Mineralocorticoid receptor antagonists (finerenone): hyperkalemia, hypotension, hyponatremia</p>
          </list-item>
          <list-item>
            <p>PDE5 inhibitors (sildenafil): visual abnormalities, hypotension, priapism, syncope</p>
          </list-item>
          <list-item>
            <p>Opioid antagonists (naloxegol): opioid withdrawal symptoms</p>
          </list-item>
          <list-item>
            <p>Sedatives/hypnotics (triazolam, oral midazolam): respiratory depression, extreme sedation</p>
          </list-item>
          <list-item>
            <p>Serotonin receptor 1A agonists/2A antagonists (flibanserin): hypotension, syncope, CNS depression</p>
          </list-item>
          <list-item>
            <p>Vasopressin receptor antagonists (tolvaptan): dehydration, hypovolemia, hyperkalemia</p>
          </list-item>
        </list>
        <p>Furthermore, nirmatrelvir/ritonavir is contraindicated with the concomitant use of medications that are CYP3A inducers, which can decrease nirmatrelvir plasma concentrations to levels that result in loss of virologic response and development of antiviral resistance. This is due to nirmatrelvir/ritonavir being a CYP3A substrate whose plasma concentration is decreased by CYP3A inducers.</p>
        <p>The following&#x000a0;is a partial list of those contraindicated medications whose coadministration with nirmatrelvir/ritonavir can result in loss of virologic response and antiviral resistance. Below is a partial list of those contraindicated medications whose coadministration with nirmatrelvir/ritonavir can result in loss of virologic response and antiviral resistance.<xref ref-type="bibr" rid="article-148244.r26">[26]</xref><xref ref-type="bibr" rid="article-148244.r27">[27]</xref>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Anticancer drugs (apalutamide)</p>
          </list-item>
          <list-item>
            <p>Anticonvulsants (carbamazepine, phenobarbital, primidone, phenytoin)</p>
          </list-item>
          <list-item>
            <p>Antimycobacterial (rifampin)</p>
          </list-item>
          <list-item>
            <p>Cystic fibrosis drugs (lumacaftor/ivacaftor)</p>
          </list-item>
          <list-item>
            <p>Herbal products (St. John's Wort)</p>
          </list-item>
        </list>
        <p>
<bold>Management of Potential Drug-drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Ritonavir decreases the conversion to clopidogrel's active metabolite, leading to inadequate inhibition of platelet aggregation. Thus, it is recommended to avoid nirmatrelvir/ritonavir in patients at very high risk of thrombosis (e.g., early period post coronary stenting) unless clopidogrel can be switched to the noninteracting drug.<xref ref-type="bibr" rid="article-148244.r28">[28]</xref><xref ref-type="bibr" rid="article-148244.r29">[29]</xref></p>
          </list-item>
          <list-item>
            <p>Ritonavir has been shown to increase rivaroxaban AUC significantly and can potentially increase the risk of bleeding; thus, concurrent administration with nirmatrelvir/ritonavir is not advised. The management of this drug interaction would require pausing rivaroxaban and&#x000a0;switching to&#x000a0;alternative agents for the anticoagulation (such as edoxaban or LMWH).<xref ref-type="bibr" rid="article-148244.r28">[28]</xref><xref ref-type="bibr" rid="article-148244.r29">[29]</xref></p>
          </list-item>
          <list-item>
            <p>In patients receiving a ritonavir-boosted regimen with a calcineurin inhibitor(tacrolimus/cyclosporine), a significant increase in tacrolimus and cyclosporine exposure has been observed, which can lead to significant toxicity. Based on the clinical data, holding tacrolimus for eight days (i.e., five days during nirmatrelvir/ritonavir treatment and three days post-treatment) is recommended.<xref ref-type="bibr" rid="article-148244.r30">[30]</xref></p>
          </list-item>
          <list-item>
            <p>According to the French Society of Pharmacology and Therapeutics, coadministration of fentanyl with nirmatrelvir/ritonavir may increase the exposure of fentanyl with the risk of severe respiratory&#x000a0;depression.<xref ref-type="bibr" rid="article-148244.r28">[28]</xref><xref ref-type="bibr" rid="article-148244.r29">[29]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-148244.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patients taking nirmatrelvir/ritonavir&#x000a0;requires close monitoring for adverse reactions, such as hypersensitivity and drug-drug interactions.<xref ref-type="bibr" rid="article-148244.r7">[7]</xref> Moreover, clinicians may consider therapeutic concentration monitoring of coadministered medications that CYP3A metabolizes. Certain medications, such as warfarin, may require additional monitoring of factors such as the international normalized ratio (INR).<xref ref-type="bibr" rid="article-148244.r31">[31]</xref> Furthermore, clinicians may consider checking renal and liver function in patients taking nirmatrelvir/ritonavir, especially those with pre-existing renal and hepatic impairment.</p>
        <p>TDM (Therapeutic drug monitoring) is required for narrow therapeutic drugs like cyclosporine and tacrolimus when coadministered with nirmatrelvir/ritonavir.<xref ref-type="bibr" rid="article-148244.r30">[30]</xref><xref ref-type="bibr" rid="article-148244.r32">[32]</xref></p>
        <p>Clinicians and healthcare facilities must be aware of mandatory reporting requirements. Prescribers are mandated to use FDA Form 3500 to report all medication errors and serious adverse events related to nirmatrelvir/ritonavir to FDA MedWatch(https://www.fda.gov/medwatch/report.htm). The adverse event must be reported to Pfizer according to the package insert. In addition, clinicians and healthcare facilities must report therapeutics information and utilization data to the US Department of Health and Human Services.</p>
        <p>Clinicians should also monitor patients&#x000a0;who complete their regimen of nirmatrelvir/ritonavir for rebound and recurrence of COVID-19 symptoms.<xref ref-type="bibr" rid="article-148244.r33">[33]</xref>&#x000a0;At this time, the mechanism, incidence, and implications of this rebound effect are unknown.&#x000a0;According to the CDC and FDA, additional treatment with nirmatrelvir/ritonavir is not required when a rebound/recurrence is suspected.<xref ref-type="bibr" rid="article-148244.r34">[34]</xref></p>
      </sec>
      <sec id="article-148244.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Nirmatrelvir/ritonavir has significant drug-drug interactions due to the ritonavir component. As a potent CYP3A inhibitor, ritonavir can increase the plasma concentrations of concomitant medications whose metabolism depends on CYP3A, increasing the risks of serious and life-threatening toxicities. In addition, ritonavir use is associated with hepatotoxicity, with reports of hepatitis, jaundice, and elevated transaminases. Patients taking nirmatrelvir/ritonavir, with or without other medications, should be monitored for drug-related toxicities.<xref ref-type="bibr" rid="article-148244.r24">[24]</xref>&#x000a0;</p>
        <p>In the event of an overdose of nirmatrelvir/ritonavir, management entails general supportive measures, including close monitoring of vital signs and observation of clinical status. There is no antidote specifically for an overdose of nirmatrelvir/ritonavir. The poison center should be contacted in the case of an overdose with nirmatrelvir/ritonavir for recommendations by medical toxicologists.<xref ref-type="bibr" rid="article-148244.r35">[35]</xref></p>
      </sec>
      <sec id="article-148244.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>As stated above, ritonavir is a potent CYP3A inhibitor with significant drug-drug interactions that can potentially cause life-threatening adverse events.<xref ref-type="bibr" rid="article-148244.r24">[24]</xref> Therefore, the healthcare team must be extremely cautious when prescribing nirmatrelvir/ritonavir to patients taking other medications. An interprofessional team of clinicians, pharmacists, nurses, and other health professionals can minimize the risk of these drug-drug interactions and improve patient-centered care, health outcomes, and patient safety.</p>
        <p>Clinicians&#x000a0;and pharmacists (authorized under the FDA EUA to prescribe nirmatrelvir/ritonavir&#x000a0;to eligible patients) should obtain a comprehensive history to determine whether patients are candidates for the medication.<xref ref-type="bibr" rid="article-148244.r36">[36]</xref>&#x000a0;Given the many known drug-drug interactions, the healthcare team should perform thorough medication reconciliation, including prescription and over-the-counter medications, herbal supplements, and recreational drugs.<xref ref-type="bibr" rid="article-148244.r37">[37]</xref></p>
        <p>If potential drug-drug interactions exist, all healthcare team members should be informed to not only help prevent adverse events but also implement any corrective measures if necessary. In addition, dose adjustments of concomitant medications might be necessary for patients at risk of drug-drug interactions or those with moderate renal impairment.<xref ref-type="bibr" rid="article-148244.r19">[19]</xref> Initial dosing and dose adjustments should be made under the guidance of a&#x000a0;clinician and pharmacist.</p>
        <p>Patients taking nirmatrelvir/ritonavir should be monitored by the interprofessional team. In addition, patients need to be provided with a fact sheet for patient education. Nurses are ideally situated to&#x000a0;observe&#x000a0;for adverse reactions, assess patient compliance with their regimen, and inform the healthcare team of their findings. However, as stated above, all healthcare team members are mandated to report serious medication errors and adverse events to FDA MedWatch and the drug's manufacturer.</p>
        <p>As nirmatrelvir/ritonavir is an investigational medicine, the healthcare team must be aware of the indications, contraindications, mechanism of action, adverse effects, toxicity, and monitoring when managing the care of patients with COVID-19. In addition to the duties mentioned above, all healthcare team members are responsible for educating and counseling patients. Given that nirmatrelvir/ritonavir is the only oral highly-effective antiviral against COVID-19 at this time, judicious use can help curb COVID-19-related morbidity and mortality while minimizing the risk of drug-related adverse events.&#x000a0;</p>
        <p>The FDA announced that pharmacists could also prescribe nirmatrelvir/ritonavir; however, patients are required to bring health records(&#x0003c;1 year old), with reports of liver and kidney function along with a comprehensive(including OTC) list of all medications, so the pharmacist can screen for potentially serious drug interactions and check for prescribing eligibility. The FDA has recommended that the pharmacist refer the patient to a physician, advanced practice nurse, or physician assistant if the above criteria are not met.</p>
        <p>Consequently, the interprofessional approach with excellent communication between physicians, advanced practice nurses, physician assistants, pharmacists, and specialists are required to accomplish optimal outcomes for nirmatrelvir/ritonavir therapy in patients with COVID-19. This includes meticulous documentation of all interactions and interventions with the patient so that all team members have the same patient data from which to make decisions regarding care.<xref ref-type="bibr" rid="article-148244.r36">[36]</xref>&#x000a0;[Level 5]</p>
        <p>Finally, genetic&#x000a0;sequencing&#x000a0;of patients treated with&#x000a0;nirmatrelvir/ritonavir is crucial due to the potential for antiviral resistance&#x000a0;to SARS-CoV-2.<xref ref-type="bibr" rid="article-148244.r17">[17]</xref> Antiviral stewardship is vital, and antivirals, including nirmatrelvir/ritonavir, should be used judiciously.<xref ref-type="bibr" rid="article-148244.r38">[38]</xref></p>
      </sec>
      <sec id="article-148244.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=148244&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=148244">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/148244/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=148244">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-148244.s11">
        <title>References</title>
        <ref id="article-148244.r1">
          <label>1</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Cascella</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rajnik</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aleem</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dulebohn</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Di Napoli</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <chapter-title>Features, Evaluation, and Treatment of Coronavirus (COVID-19)</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>18</day>
            <pub-id pub-id-type="pmid">32150360</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148244.r2">
          <label>2</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Aleem</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Akbar Samad</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Vaqar</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <chapter-title>Emerging Variants of SARS-CoV-2 and Novel Therapeutics Against Coronavirus (COVID-19)</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">34033342</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148244.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lamb</surname>
                <given-names>YN</given-names>
              </name>
            </person-group>
            <article-title>Nirmatrelvir Plus Ritonavir: First Approval.</article-title>
            <source>Drugs</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>82</volume>
            <issue>5</issue>
            <fpage>585</fpage>
            <page-range>585-591</page-range>
            <pub-id pub-id-type="pmid">35305258</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148244.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kompaniyets</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Belay</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Freedman</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Sucosky</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Lange</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Gundlapalli</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Boehmer</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Blanck</surname>
                <given-names>HM</given-names>
              </name>
            </person-group>
            <article-title>Body Mass Index and Risk for COVID-19-Related Hospitalization, Intensive Care Unit Admission, Invasive Mechanical Ventilation, and Death - United States, March-December 2020.</article-title>
            <source>MMWR Morb Mortal Wkly Rep</source>
            <year>2021</year>
            <month>Mar</month>
            <day>12</day>
            <volume>70</volume>
            <issue>10</issue>
            <fpage>355</fpage>
            <page-range>355-361</page-range>
            <pub-id pub-id-type="pmid">33705371</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148244.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harrison</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Fazio-Eynullayeva</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lane</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Underhill</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lip</surname>
                <given-names>GYH</given-names>
              </name>
            </person-group>
            <article-title>Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis.</article-title>
            <source>PLoS Med</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>17</volume>
            <issue>9</issue>
            <fpage>e1003321</fpage>
            <pub-id pub-id-type="pmid">32911500</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148244.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ioannou</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Locke</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Berry</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>O'Hare</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Crothers</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Eastment</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Dominitz</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Fan</surname>
                <given-names>VS</given-names>
              </name>
            </person-group>
            <article-title>Risk Factors for Hospitalization, Mechanical Ventilation, or Death Among 10&#x0202f;131 US Veterans With SARS-CoV-2 Infection.</article-title>
            <source>JAMA Netw Open</source>
            <year>2020</year>
            <month>Sep</month>
            <day>01</day>
            <volume>3</volume>
            <issue>9</issue>
            <fpage>e2022310</fpage>
            <pub-id pub-id-type="pmid">32965502</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148244.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hammond</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Leister-Tebbe</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gardner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abreu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bao</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wisemandle</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Baniecki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hendrick</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Damle</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sim&#x000f3;n-Campos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pypstra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rusnak</surname>
                <given-names>JM</given-names>
              </name>
              <collab>EPIC-HR Investigators</collab>
            </person-group>
            <article-title>Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.</article-title>
            <source>N Engl J Med</source>
            <year>2022</year>
            <month>Apr</month>
            <day>14</day>
            <volume>386</volume>
            <issue>15</issue>
            <fpage>1397</fpage>
            <page-range>1397-1408</page-range>
            <pub-id pub-id-type="pmid">35172054</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148244.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mahase</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports.</article-title>
            <source>BMJ</source>
            <year>2021</year>
            <month>Nov</month>
            <day>08</day>
            <volume>375</volume>
            <fpage>n2713</fpage>
            <pub-id pub-id-type="pmid">34750163</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148244.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gottlieb</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Vaca</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Paredes</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mera</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Webb</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Perez</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Oguchi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>BU</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hidalgo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sachdeva</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mittal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Osiyemi</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Skarbinski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Juneja</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hyland</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Osinusi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Camus</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Abdelghany</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Behenna-Renton</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Duff</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Marty</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Ginde</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Schiffer</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>JA</given-names>
              </name>
              <collab>GS-US-540-9012 (PINETREE) Investigators</collab>
            </person-group>
            <article-title>Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.</article-title>
            <source>N Engl J Med</source>
            <year>2022</year>
            <month>Jan</month>
            <day>27</day>
            <volume>386</volume>
            <issue>4</issue>
            <fpage>305</fpage>
            <page-range>305-315</page-range>
            <pub-id pub-id-type="pmid">34937145</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148244.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jayk Bernal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gomes da Silva</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Musungaie</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Kovalchuk</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Delos Reyes</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;n-Quir&#x000f3;s</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Caraco</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Williams-Diaz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Du</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pedley</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Assaid</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Strizki</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Grobler</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Shamsuddin</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Tipping</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Paschke</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Butterton</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>De Anda</surname>
                <given-names>C</given-names>
              </name>
              <collab>MOVe-OUT Study Group</collab>
            </person-group>
            <article-title>Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.</article-title>
            <source>N Engl J Med</source>
            <year>2022</year>
            <month>Feb</month>
            <day>10</day>
            <volume>386</volume>
            <issue>6</issue>
            <fpage>509</fpage>
            <page-range>509-520</page-range>
            <pub-id pub-id-type="pmid">34914868</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148244.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vangeel</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chiu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>De Jonghe</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Maes</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Slechten</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Raymenants</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Andr&#x000e9;</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Leyssen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Neyts</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jochmans</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern.</article-title>
            <source>Antiviral Res</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>198</volume>
            <fpage>105252</fpage>
            <pub-id pub-id-type="pmid">35085683</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148244.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ullrich</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ekanayake</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Otting</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nitsche</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir.</article-title>
            <source>Bioorg Med Chem Lett</source>
            <year>2022</year>
            <month>Apr</month>
            <day>15</day>
            <volume>62</volume>
            <fpage>128629</fpage>
            <pub-id pub-id-type="pmid">35182772</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148244.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuehn</surname>
                <given-names>BM</given-names>
              </name>
            </person-group>
            <article-title>Rehospitalization, Emergency Visits After Paxlovid Treatment Are Rare.</article-title>
            <source>JAMA</source>
            <year>2022</year>
            <month>Jul</month>
            <day>26</day>
            <volume>328</volume>
            <issue>4</issue>
            <fpage>323</fpage>
            <pub-id pub-id-type="pmid">35881113</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148244.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Malden</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lewin</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Ackerson</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Lipsitch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lewnard</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Tartof</surname>
                <given-names>SY</given-names>
              </name>
            </person-group>
            <article-title>Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment - California, December 2021-May 2022.</article-title>
            <source>MMWR Morb Mortal Wkly Rep</source>
            <year>2022</year>
            <month>Jun</month>
            <day>24</day>
            <volume>71</volume>
            <issue>25</issue>
            <fpage>830</fpage>
            <page-range>830-833</page-range>
            <pub-id pub-id-type="pmid">35737591</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148244.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marzi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vakil</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Bahmanyar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zarenezhad</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Paxlovid: Mechanism of Action, Synthesis, and <italic>In Silico</italic> Study.</article-title>
            <source>Biomed Res Int</source>
            <year>2022</year>
            <volume>2022</volume>
            <fpage>7341493</fpage>
            <pub-id pub-id-type="pmid">35845944</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148244.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fishbane</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hirsch</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Nair</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Special Considerations for Paxlovid Treatment Among Transplant Recipients With SARS-CoV-2 Infection.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>79</volume>
            <issue>4</issue>
            <fpage>480</fpage>
            <page-range>480-482</page-range>
            <pub-id pub-id-type="pmid">35032591</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148244.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Gribenko</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Perrin</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Cardin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Liberator</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Hao</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Genetic Surveillance of SARS-CoV-2 M<sup>pro</sup> Reveals High Sequence and Structural Conservation Prior to the Introduction of Protease Inhibitor Paxlovid.</article-title>
            <source>mBio</source>
            <year>2022</year>
            <month>Aug</month>
            <day>30</day>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>e0086922</fpage>
            <pub-id pub-id-type="pmid">35862764</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148244.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hung</surname>
                <given-names>YP</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Chiu</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>IL</given-names>
              </name>
              <name>
                <surname>Ko</surname>
                <given-names>WC</given-names>
              </name>
            </person-group>
            <article-title>Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?</article-title>
            <source>Antibiotics (Basel)</source>
            <year>2022</year>
            <month>Feb</month>
            <day>09</day>
            <volume>11</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">35203821</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148244.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Toussi</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Neutel</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Navarro</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Preston</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kavetska</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>LaBadie</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Binks</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>PLS</given-names>
              </name>
              <name>
                <surname>Demers</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Corrigan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Damle</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID-19, in Subjects With Renal Impairment.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>112</volume>
            <issue>4</issue>
            <fpage>892</fpage>
            <page-range>892-900</page-range>
            <pub-id pub-id-type="pmid">35712797</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148244.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Inker</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Eneanya</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Coresh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tighiouart</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Crews</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Doria</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Estrella</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Froissart</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grams</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Greene</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Grubb</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gudnason</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Guti&#x000e9;rrez</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>Kalil</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Karger</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Mauer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Navis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Poggio</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Rodby</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rossing</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rule</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Selvin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Seegmiller</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Shlipak</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Torres</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ballew</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Couture</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Powe</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Levey</surname>
                <given-names>AS</given-names>
              </name>
              <collab>Chronic Kidney Disease Epidemiology Collaboration</collab>
            </person-group>
            <article-title>New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race.</article-title>
            <source>N Engl J Med</source>
            <year>2021</year>
            <month>Nov</month>
            <day>04</day>
            <volume>385</volume>
            <issue>19</issue>
            <fpage>1737</fpage>
            <page-range>1737-1749</page-range>
            <pub-id pub-id-type="pmid">34554658</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148244.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Delgado</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Baweja</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Crews</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Eneanya</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Gadegbeku</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Inker</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Mendu</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Moxey-Mims</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>GV</given-names>
              </name>
              <name>
                <surname>St Peter</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Warfield</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Powe</surname>
                <given-names>NR</given-names>
              </name>
            </person-group>
            <article-title>A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>79</volume>
            <issue>2</issue>
            <fpage>268</fpage>
            <page-range>268-288.e1</page-range>
            <pub-id pub-id-type="pmid">34563581</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148244.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Catlin</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Bowman</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Campion</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Nowland</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Sathish</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Stethem</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Updyke</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cappon</surname>
                <given-names>GD</given-names>
              </name>
            </person-group>
            <article-title>Reproductive and developmental safety of nirmatrelvir (PF-07321332), an oral SARS-CoV-2 M<sup>pro</sup> inhibitor in animal models.</article-title>
            <source>Reprod Toxicol</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>108</volume>
            <fpage>56</fpage>
            <page-range>56-61</page-range>
            <pub-id pub-id-type="pmid">35101563</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148244.r23">
          <label>23</label>
          <element-citation publication-type="book">
            <chapter-title>Nirmatrelvir</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">35073029</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148244.r24">
          <label>24</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Talha</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Dhamoon</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <chapter-title>Ritonavir</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">31335032</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148244.r25">
          <label>25</label>
          <element-citation publication-type="book">
            <chapter-title>Paxlovid</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2022</year>
            <month>1</month>
            <day>31</day>
            <pub-id pub-id-type="pmid">35138785</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148244.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ross</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Bortolussi-Courval</surname>
                <given-names>&#x000c9;</given-names>
              </name>
              <name>
                <surname>Hanula</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Goodwin Wilson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McDonald</surname>
                <given-names>EG</given-names>
              </name>
            </person-group>
            <article-title>Drug Interactions With Nirmatrelvir-Ritonavir in Older Adults Using Multiple Medications.</article-title>
            <source>JAMA Netw Open</source>
            <year>2022</year>
            <month>Jul</month>
            <day>01</day>
            <volume>5</volume>
            <issue>7</issue>
            <fpage>e2220184</fpage>
            <pub-id pub-id-type="pmid">35793089</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148244.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Azanza</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Mensa</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez Del Castillo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Linares Rufo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Molero</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Madero Valle</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Barber&#x000e1;n</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Interactions listed in the Paxlovid fact sheet, classified according to risks, pharmacological groups, and consequences.</article-title>
            <source>Rev Esp Quimioter</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>35</volume>
            <issue>4</issue>
            <fpage>357</fpage>
            <page-range>357-361</page-range>
            <pub-id pub-id-type="pmid">35822605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148244.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marzolini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kuritzkes</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Marra</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Boyle</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gibbons</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Flexner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pozniak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boffito</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Waters</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Burger</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Back</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Khoo</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>112</volume>
            <issue>6</issue>
            <fpage>1191</fpage>
            <page-range>1191-1200</page-range>
            <pub-id pub-id-type="pmid">35567754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148244.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lemaitre</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gr&#x000e9;goire</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Monchaud</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bouchet</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Saint-Salvi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Polard</surname>
                <given-names>E</given-names>
              </name>
              <collab>SFPT Therapeutic Drug Monitoring and Treatment Personalization group (STP-PT) of the French Society of Pharmacology and Therapeutics (SFPT)</collab>
              <collab>French Pharmacovigilance Network (CRPV)</collab>
              <collab>ANRS-MIE AC-43 Clinical Pharmacology Committee, joint working group</collab>
              <collab>SFPT Therapeutic Drug Monitoring and Treatment Personalization group (STP-PT) of the French Society of Pharmacology and Therapeutics (SFPT)</collab>
              <collab>French Pharmacovigilance Network (CRPV)</collab>
              <collab>ANRS-MIE AC-43 Clinical Pharmacology Committee, joint working group</collab>
            </person-group>
            <article-title>Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT).</article-title>
            <source>Therapie</source>
            <year>2022</year>
            <season>Sep-Oct</season>
            <volume>77</volume>
            <issue>5</issue>
            <fpage>509</fpage>
            <page-range>509-521</page-range>
            <pub-id pub-id-type="pmid">35618549</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148244.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salerno</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Jennings</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Lange</surname>
                <given-names>NW</given-names>
              </name>
              <name>
                <surname>Kovac</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Shertel</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Hedvat</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Scheffert</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Pereira</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients.</article-title>
            <source>Am J Transplant</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>22</volume>
            <issue>8</issue>
            <fpage>2083</fpage>
            <page-range>2083-2088</page-range>
            <pub-id pub-id-type="pmid">35278260</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148244.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>ECY</given-names>
              </name>
            </person-group>
            <article-title>Physiologically-Based Pharmacokinetic Modeling-Guided Dose Management of Oral Anticoagulants when Initiating Nirmatrelvir/Ritonavir (Paxlovid) for COVID-19 Treatment.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>112</volume>
            <issue>4</issue>
            <fpage>803</fpage>
            <page-range>803-807</page-range>
            <pub-id pub-id-type="pmid">35712802</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148244.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lange</surname>
                <given-names>NW</given-names>
              </name>
              <name>
                <surname>Salerno</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Jennings</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Choe</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hedvat</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kovac</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Scheffert</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shertel</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ratner</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Pereira</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Nirmatrelvir/ritonavir use: Managing clinically significant drug-drug interactions with transplant immunosuppressants.</article-title>
            <source>Am J Transplant</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>22</volume>
            <issue>7</issue>
            <fpage>1925</fpage>
            <page-range>1925-1926</page-range>
            <pub-id pub-id-type="pmid">35015924</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148244.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coulson</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>COVID-19 "Rebound" associated with nirmatrelvir/ritonavir pre-hospital therapy.</article-title>
            <source>J Infect</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>85</volume>
            <issue>4</issue>
            <fpage>436</fpage>
            <page-range>436-480</page-range>
            <pub-id pub-id-type="pmid">35718206</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148244.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rubin</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>From Positive to Negative to Positive Again-The Mystery of Why COVID-19 Rebounds in Some Patients Who Take Paxlovid.</article-title>
            <source>JAMA</source>
            <year>2022</year>
            <month>Jun</month>
            <day>28</day>
            <volume>327</volume>
            <issue>24</issue>
            <fpage>2380</fpage>
            <page-range>2380-2382</page-range>
            <pub-id pub-id-type="pmid">35675094</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148244.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Neumann</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Chai</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Greller</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Mycyk</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>Medical Toxicology and COVID-19: Our Role in a Pandemic.</article-title>
            <source>J Med Toxicol</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>245</fpage>
            <page-range>245-247</page-range>
            <pub-id pub-id-type="pmid">32356251</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148244.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tanne</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Covid-19: FDA authorises pharmacists to prescribe Paxlovid.</article-title>
            <source>BMJ</source>
            <year>2022</year>
            <month>Jul</month>
            <day>08</day>
            <volume>378</volume>
            <fpage>o1695</fpage>
            <pub-id pub-id-type="pmid">35803606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148244.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marzolini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kuritzkes</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Marra</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Boyle</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gibbons</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Flexner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pozniak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boffito</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Waters</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Burger</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Back</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Khoo</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions.</article-title>
            <source>Ann Intern Med</source>
            <year>2022</year>
            <month>May</month>
            <volume>175</volume>
            <issue>5</issue>
            <fpage>744</fpage>
            <page-range>744-746</page-range>
            <pub-id pub-id-type="pmid">35226530</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148244.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mazonakis</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tsioutis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Markaki</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Papadakis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Papadakos</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Spernovasilis</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Coronavirus disease 2019 (COVID-19) oral antivirals stewardship: Establishing game rules.</article-title>
            <source>Infect Control Hosp Epidemiol</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>43</volume>
            <issue>12</issue>
            <fpage>1990</fpage>
            <page-range>1990-1992</page-range>
            <pub-id pub-id-type="pmid">35115067</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
